Navigation Links
Dmitry Medvedev Presented BIOCAD the First National "Industry" Award
Date:7/10/2014

ST. PETERSBURG, Russia, July 10, 2014 /PRNewswire/ --

On July 9 Prime Minister of the Russian Federation Dmitry Medvedev, presented Russia's first national "Industry" award to a biopharmaceutical company BIOCAD. The Company is developing a unique project called MabNext. Within the scope of MabNext project BIOCAD develops a number of innovative drugs based on monoclonal antibodies for treatment of cancer and autoimmune diseases. The ceremony took place at the International Exhibition "Innoprom 2014" in Ekaterinburg.

     (Logo: http://photos.prnewswire.com/prnh/20140514/686712)

     (Photo: http://photos.prnewswire.com/prnh/20140710/696843 )

According to the Russian Ministry of Health, in the last 12 years the number of new cases of malignant tumors has increased by 11%. The steady increase in the number of cancer patients is a global trend. According to the International Agency for Research on Cancer, in the next 20 years the number of new oncology patients in the world will reach the figure of 22 million cases per year.  Therefore, Russia and the rest of the world are so desperately in need of new effective drugs that will help to overcome serious illnesses and save millions of lives.

BIOCAD is developing a wide portfolio of innovative products based on monoclonal antibodies for treatment of diseases such as breast cancer, colorectal cancer, lung cancer, melanoma, multiple sclerosis, rheumatoid arthritis and psoriasis.

"Now the country is undergoing fundamental changes regarding availability of modern drugs for its people. Thanks to the support of Ministry of Industry and Trade, Ministry of Health, Ministry of Economic Development, Russian pharmaceutical companies are creating a powerful technologic basis for the production of innovative products and are competing successfully on the global pharmaceutical market. Of course, our foreign colleagues are not happy with this. However, now we can deliver innovative medicines that have no analogues in the world. The project MabNext is a bright example of this," said Dmitriy Morozov, CEO of BIOCAD.

The main advantage of products based on monoclonal antibodies, is that they affect only selected cells or molecules, in other words, these are targeted therapies.  Only relevant targets are neutralized without affecting the healthy cells.

BIOCAD has more than 10 of such innovative products based on monoclonal antibodies at different stages of development. One of the most noticeable ones is an antibody specific for interleukin 17. Clinical trials of this drug will begin in 2014. The drug has no analogues on the market and its characteristics are superior to anti-IL17 antibodies being developed by foreign companies. This product has huge potential when it comes to the treatment of socially significant diseases such as rheumatoid arthritis and psoriasis.

If we talk about cancer - the company is at the stage of developing original products based on monoclonal antibodies against targets such as PD-1, HER3, Ang-2 and others. Antibodies for PD-1 increase ability of patient's immune system to recognize and destroy tumor cells.


'/>"/>
SOURCE BIOCAD
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
2. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
3. Startling results in synthetic chemistry presented in Nature Chemistry
4. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
5. New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 Congress
6. Top Contenders For the First Annual 2012 Fright Night Awards Presented By Cancer Bites Announced
7. Promising Data Presented on GenVec Malaria Program
8. Amgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting
9. Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
10. Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 and Phase 2 Trials Suggest High and Durable Response in Chronic Lymphocytic Leukemia
11. Data on the Selexis SUREtechnology Platform to be Presented at PEPTALK 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)...  The Maryland House of Delegates and House Speaker ... of Maryland School of Medicine Dean E. Albert ... Medical System President and CEO Robert Chrencik , ... honor given to the public by the leader of ... and Mr. Chrencik for their contributions to our ...
(Date:2/10/2016)... (PRWEB) , ... February 10, ... ... REGN) today announced that it has joined the Human Vaccines Project, a ... infectious diseases and cancer. , The Human Vaccines Project brings together ...
(Date:2/10/2016)... 2016  Matchbook, Inc., a company specializing in ... companies, announced today the appointment of Jim ... brings nearly 25 years of experience in supply ... nearly two decades in executive level roles as ... Genzyme and, most recently headed global logistics and ...
(Date:2/10/2016)... ... February 10, 2016 , ... LATHAM, NEW YORK... Marktech Optoelectronics ... Photonics West conference in San Francisco’s Moscone Center from February 16-18, 2016, and ... , These latest InGaAs PIN diode standard packages feature a TO-46 metal can ...
Breaking Biology Technology:
(Date:2/1/2016)... Rising sales of consumer electronics ... intuitive gesture control market size ... consumer electronics coupled with new technological advancements to drive ... through 2020   --> ... advancements to drive global touchfree intuitive gesture control market ...
(Date:1/27/2016)... CHESTER, Ohio , Jan. 27, 2016  Rite ... supplier based in West Chester, Ohio ... their award winning service staff, based in ... technical capacity and ability to provide modifications, installations and ... John Dovalina , CEO of PLUS, commented, "PLUS has ...
(Date:1/22/2016)... , Jan. 22, 2016 ... addition of the "Global Biometrics Market ... their offering. --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ... "Global Biometrics Market in Retail Sector ... --> Research and Markets ( ...
Breaking Biology News(10 mins):